The success of Sildenafil initially sparked a period of growth for major pharmaceutical companies, nevertheless recent changes present a complicated outlook for shareholders. Off-patent versions are eroding earnings, https://deweydnnj877411.thekatyblog.com/39369403/sildenafil-and-big-pharma-a-precarious-bet